Cannabinoids for the treatment of dementia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Krishnan, Sarada ^a   Cairns, Ruth ^a   Howard, Robert ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DONEPEZIL; DRONABINOL; PLACEBO;

CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITION; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; HUMAN; META ANALYSIS; NERVE DEGENERATION; NEUROPROTECTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 55049106410     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007204     Document Type: Review

References (27)

1. Baker 2003 Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. The Lancet Neurology 2003;2:291-8.
2. Ballard 2006 Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1.[Art. No.: CD003476. DOI: 10.1002/14651858.CD003476.pub2]
3. Birks 2006 Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1.[Art. No.: CD005593. DOI: 10.1002/14651858.CD005593]
4. Campbell 2007 Campbell VA, Gowran A. Alzheimer's disease; taking the edge off with cannabinoids?. British Journal of Pharmacology 2007;152:655-662.
5. Ehrhart 2005 Ehrhart J, Obergon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD. Stimulation of CB2 suppressesmicroglial activation. Journal of Neuroinflammation 2005;2:29.
6. Eubanks 2006 Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, Dickerson TJ, et al.A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular Pharmaceutics 2006;3:773-7.
7. FDA 2005 Centre for Drug Evaluation and Research. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioural disturbances. FDA April 2005.
8. Grinspoon 1993 Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven, CT: Yale University Press, 1993.
9. Grundy 2002 Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opinion on Investigational Drugs 2002;11:1365-74.
10. Hampson 1998 Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 1998;95:8268-73.
11. Howard 2007 Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al.Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine 2007;357:1382-92.
12. Howlett 2002 Howlett AC, Barth F, Bonner T, Cabral G, Casellas P, Devane WA, et al.International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002;54:161-202.
13. Iversen 2000 Iversen LL.The science of marijuana. Oxford: Oxford University Press, 2000.
14. Lowin 2001 Lowin A, Knapp M, McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. International Journal of Geriatric Psychiatry 2001;16:1143-8.
15. Matsuda 1990 Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
16. MHRA 2004 Medicines and Healthcare Products Regulatory Agency. New advice issued on risperidone and olanzepine. MHRA March 2004.
17. Nagayama 1999 Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al.Cannabinoids and neuroprotection in global and focal cerebral ischaemia and in neuronal cultures. Journal of Neuroscience 1999;19:2987-95.
18. Onaivi 2006 Onaivi ES. Neuropsychological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006;54:231-246.
19. Rabins 1982 Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. Journal of the American Medical Society 1982;248:333-5.
20. Ramirez 2005 Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos M. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. The Journal of Neuroscience 2005;25:1904-13.
21. Schneider 2005 Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005;294:1934-43.
22. Schneider 2006 Schneider LS, Dagerman KS, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized placebo-controlled trials. American Journal of Geriatric Psychiatry 2006;14:191-210.
23. Shen 1998 Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Molecular Pharmacology 1998;54:459-62.
24. Steele 1990 Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 1990;147:1049-51.
25. Van Sickle 2005 Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al.Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-332.
26. Volicer 1997 Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 1997;12:913-9.
27. Walther 2006 Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 2006;185:524-8.